BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Neupro (rotigotine) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Neupro (rotigotine)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06291116-1747@assetmemo.bio
DTSTAMP:20261121T004552Z
DTSTART;VALUE=DATE:20300701
DTEND;VALUE=DATE:20300702
SUMMARY:Neupro (rotigotine): Phase 2 readout est. (NCT06291116)
DESCRIPTION:Neupro (rotigotine)\, phase 2.\nStudy: Safety of RotigotiNe in 
 Patients With Autosomal Dominant Polycystic Kidney Disease\nEstimated prim
 ary completion: 1 July 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/rotigotine#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06291116
URL:https://assetmemo.bio/drug/rotigotine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
